Successful skipping of abnormal pseudoexon by antisense oligonucleotides in vitro for a patient with beta-propeller protein-associated neurodegeneration

• Published in: Scientific reports Vol. 14; no. 1; p. 6506
• Main Authors: Yamada, Mamiko, Maeta, Kazuhiro, Suzuki, Hisato, Kurosawa, Ryo, Takenouchi, Toshiki, Awaya, Tomonari, Ajiro, Masahiko, Takeuchi, Atsuko, Nishio, Hisahide, Hagiwara, Masatoshi, Miya, Fuyuki, Matsuo, Masafumi, Kosaki, Kenjiro
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 18.03.2024; Nature Publishing Group; Nature Portfolio
• Subjects: 631/208/212/2019; 631/208/366; Adolescent; Antisense oligonucleotides; Carrier Proteins - genetics; Chromosomes; Exon skipping; Exons - genetics; Extrapyramidal system; Female; Genomes; Globus pallidus; Humanities and Social Sciences; Humans; Magnetic resonance imaging; multidisciplinary; Mutation; Neurodegeneration; Neurodegenerative diseases; Oligonucleotides, Antisense - genetics; Oligonucleotides, Antisense - pharmacology; RNA Splicing; Science; Science (multidisciplinary); Substantia nigra; Transfection; Whole genome sequencing
• ISSN: 2045-2322; 2045-2322
• DOI: 10.1038/s41598-024-56704-z

Pathogenic variants in WDR45 on chromosome Xp11 cause neurodegenerative disorder beta-propeller protein-associated neurodegeneration (BPAN). Currently, there is no effective therapy for BPAN. Here we report a 17-year-old female patient with BPAN and show that antisense oligonucleotide (ASO) was effective in vitro. The patient had developmental delay and later showed extrapyramidal signs since the age of 15 years. MRI findings showed iron deposition in the globus pallidus and substantia nigra on T2 MRI. Whole genome sequencing and RNA sequencing revealed generation of pseudoexon due to inclusion of intronic sequences triggered by an intronic variant that is remote from the exon–intron junction: WDR45 (OMIM #300526) chrX(GRCh37):g.48935143G > C, (NM_007075.4:c.235 + 159C > G). We recapitulated the exonization of intron sequences by a mini-gene assay and further sought antisense oligonucleotide that induce pseudoexon skipping using our recently developed, a dual fluorescent splicing reporter system that encodes two fluorescent proteins, mCherry, a transfection marker designed to facilitate evaluation of exon skipping and split eGFP, a splicing reaction marker. The results showed that the 24-base ASO was the strongest inducer of pseudoexon skipping. Our data presented here have provided supportive evidence for in vivo preclinical studies.